264 completed, 16 unknown, 13 terminated, 11 not yet recruiting. 324 Phase 1, 71 Phase 2.
Follow Malaria: new trials by email Literature Review of Malaria trials Research Report on Malaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Challenge Trial of PfSPZ-LARC2 Vaccine in Burkina Faso PfSPZ-LARC2 Vaccine, PfSPZ Challenge, Normal Saline - Malaria (Plasmodium Falciparum) | Phase 1 | Not yet recruiting | Sanaria Inc. | 45 | 2027-03-01 | 2026-07-31 |
| Transmission-Blocking Vaccine Pvs230D1-EPA/Matrix-M in Healthy Malaria-Naive Adults Using a Plasmodium Vivax Controlled Human Malaria Infection and Transmission Model Plasmodium vivax Challenge Agent Derived from PvHMB-CCE001, Pvs230D1-EPA/Matrix-M - Healthy Volunteers, Malaria | Phase 1 / Phase 2 | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 220 | 2026-11-18 | 2026-11-13 |
| Malaria CVD 36000; Gates INV090205 PfSPZ Challenge (NF54), Wearable Biosensor Devices, Placebo - Malaria (Plasmodium Falciparum) | Phase 1 | Not yet recruiting | University of Maryland, Baltimore | 32 | 2026-11-01 | 2026-09-09 |
| A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults Piperaquine, Artesunate-pyronaridine (Pyramax), Piperaquine and artesunate-pyronaridine (Pyramax) - Malaria | Phase 1 | Not yet recruiting | University of Oxford | 24 | 2026-11-01 | 2026-08-05 |
| Safety and Immunogenicity of the Recombinant Malaria Vaccines in Healthy Adults Aged 18-50 Years LYB014 low dose, LYB014 high dose, LYB017 low dose - Malaria Vaccine | Phase 1 | Not yet recruiting | Guangzhou Patronus Biotech Co., Ltd. | 72 | 2026-10-01 | 2026-10-22 |
| Safety, Tolerability, Pharmacokinetics, and Mosquitocidal Activity of Lotilaner in Healthy Participants in Mali. Cohort 1 low dose lotilaner with a high-fat meal, Cohort 1 low dose placebo with a high-fat meal, Cohort 2 high dose lotilaner in fasted state - Malaria | Phase 1 | Recruiting | Medicines for Malaria Venture | 75 | 2026-09-14 | 2026-09-24 |
| Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) PfSPZ Vaccine, PfSPZ Diluent, Normal Saline - Malaria | Phase 1 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-09-14 | 2026-09-16 | |
| Artemisia Annua Infusion for the Treatment of Asymptomatic Plasmodium Falciparum Infection Artemisia Annua Leaf, Centaurii herba - Asymptomatic P.Falciparum Malaria | Phase 1 | Not yet recruiting | Centre de Recherche Médicale de Lambaréné | 20 | 2026-09-01 | 2026-09-15 |
| Safety and PK of MMV371 LAI in Healthy Adults and Adolescents in Rwanda MMV371, Placebo for MMV371 - Malaria (Plasmodium Falciparum), Malaria Falciparum | Phase 1 | Not yet recruiting | Medicines for Malaria Venture | 80 | 2026-09-01 | 2026-04-23 |
| First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults GSK4425689A SC, GSK4425689A IV, Placebo - Malaria, Falciparum | Phase 1 | Recruiting | GlaxoSmithKline | 40 | 2026-07-27 | 2026-10-05 |
| Drug-Interaction Assessment of GSK3772701 in Healthy Male and Female Participants Aged 18 to 55 Years Midazolam (MDZ), GSK3772701 - Malaria, Falciparum | Phase 1 | Completed | GlaxoSmithKline | 20 | 2026-06-26 | 2026-09-30 |
| A Challenge Study to Assess the Blood-stage Efficacy of Full-length SUM-101 Malaria Vaccine Candidate SUM-101, CHMI, Verorab® - Malaria Fever | Phase 1 | Withdrawn | European Vaccine Initiative | 2026-03-20 | 2026-09-11 | |
| Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults Normal Saline (Placebo), PfSPZ-LARC2 Vaccine, PfSPZ Challenge (7G8) - Malaria Falciparum | Phase 1 | Recruiting | Sanaria Inc. | 42 | 2026-03-12 | 2026-11-03 |
| A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine) R21, RH5.1, R78C - Malaria,Falciparum | Phase 1 | Active not recruiting | University of Oxford | 56 | 2025-09-15 | 2026-10-21 |
| Clinical Trial to Evaluate the Safety and Immunogenicity of the Vivaxin Vaccine for Malaria Caused by Plasmodium Vivax." Vivaxin vaccine manufactured by CT Vacinas/Cristália Laboratory, Placebo - Malaria Vivax | Phase 1 | Not yet recruiting | Federal University of Minas Gerais | 48 | 2025-09-01 | 2025-09-15 |
| Safety and Immunogenicity of SUM-101 Malaria Vaccine in Children and Infants Living in Burkina Faso SUM-101 - Malaria,Falciparum | Phase 1 | Completed | European Vaccine Initiative | 39 | 2025-08-01 | 2026-09-11 |
| First-in-Human PfSPZ-LARC2 Vaccination/CHMI PfSPZ Vaccine, PfSPZ (7G8) Challenge, Sodium Chloride, 0.9% - Malaria | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 22 | 2025-07-23 | 2026-08-17 |
| Controlled Human Malaria Infection by Mosquito Bites Using a Local Strain of Plasmodium Falciparum Controlled Human Malaria Infection - Malaria (Plasmodium Falciparum) | Phase 1 | Completed | Centre de Recherche Médicale de Lambaréné | 20 | 2025-07-18 | 2026-09-11 |
| Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M Adjuvant Pfs25-IMX313, Pfs48/45 - Plasmodium Falciparum Malaria | Phase 1 / Phase 2 | Active not recruiting | University of Oxford | 56 | 2025-07-07 | 2026-02-23 |
| Experimental Malaria Infection of Healthy Malaria-Naive Adults by Mosquito Bite With the Genetically Modified Plasmodium Falciparum NF54/iGP3 GAP NF54/iGP3 - Malaria Falciparum, Malaria Infection | Phase 1 | Not yet recruiting | University of Melbourne | 2 | 2025-07-01 | 2025-03-18 |
Showing 20 of 324. Sign in to see all of them.
Malaria, Falciparum (137) · Malaria, Vivax (19) · Parasitemia (10) · Infections (7) · Parasitic Diseases (5) · Malaria, Cerebral (4) · Protozoan Infections (4) · Burkitt Lymphoma (3) · Vector Borne Diseases (3) · Adenoviridae Infections (2) · Glucosephosphate Dehydrogenase Deficiency (2) · HIV Infections (2) · HIV Seropositivity (2) · Hemolysis (2)
Mosquito-Borne Diseases (324) · Vector Borne Diseases (321) · Protozoan Infections (320) · Parasitic Diseases (319) · Infections (317) · Pathological Conditions, Signs and Symptoms (15) · Pathologic Processes (13) · Sepsis (10) · Inflammation (9) · Systemic Inflammatory Response Syndrome (9) · Virus Diseases (9) · Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · DNA Virus Infections (5)
Saline Solution (19) · Artemether, Lumefantrine Drug Combination (13) · Primaquine (12) · Matrix-M (11) · Chloroquine (9) · fanasil, pyrimethamine drug combination (8) · Aluminum Hydroxide (7) · Rabies Vaccines (7) · Sodium Chloride (7) · artefenomel (7) · Artesunate (6) · piperaquine (6) · pyronaridine tetraphosphate, artesunate drug combination (6) · Lumefantrine (5) · MMV390048 (5)
University of Oxford (55) · National Institute of Allergy and Infectious Diseases (NIAID) (52) · Medicines for Malaria Venture (44) · U.S. Army Medical Research and Development Command (24) · Sanaria Inc. (23) · GlaxoSmithKline (14) · European Vaccine Initiative (6) · Novartis Pharmaceuticals (6) · Radboud University Medical Center (6) · African Malaria Network Trust (5) · London School of Hygiene and Tropical Medicine (5) · Swiss Tropical & Public Health Institute (4) · Centre de Recherche Médicale de Lambaréné (3) · Pfizer (3) · Seattle Children's Hospital (3)
United States (87) · United Kingdom (54) · Mali (28) · Australia (25) · Burkina Faso (15) · Tanzania (13) · Netherlands (12) · Kenya (9) · Gabon (8) · Switzerland (8) · Germany (7) · Thailand (6) · The Gambia (6) · France (4) · Uganda (4)
Patrick E Duffy, M.D. (8) · James McCarthy, Prof (6) · Adrian VS Hill, D.Phil, FRCP (5) · Adrian V S Hill, MD (4) · Ulrike Lorch, MD FRCA FFPM (4) · Adrian V Hill, DPhill FRCP (3) · Adrian VS Hill (3) · Adrian VS Hill, MA, BM BCh, DPhil, DM (3) · Blaise Genton, MD PhD (3) · Isabelle Borghini Fuhrer, PhD (3) · Judith Epstein, MD (3) · Peter Kremsner, MD, PhD (3)
PMID 39787798, PMID 31932368, PMID 40245769, PMID 41014333, PMID 23526949, PMID 23899517, PMID 25211344, PMID 26292027, PMID 26292257, PMID 27695088, PMID 29389671, PMID 32239164, PMID 32275867, PMID 33717176, PMID 34179977, PMID 34194041, PMID 39324693, PMID 39708824, PMID 39805302, PMID 41176969, PMID 10190913, PMID 10501745, PMID 12663340, PMID 12742586, PMID 1313024, PMID 15069048, PMID 16904798, PMID 17075340, PMID 17428147, PMID 17925866, PMID 17940609, PMID 18060072, PMID 18213374, PMID 18231580, PMID 18253503, PMID 18270560, PMID 18378716, PMID 18419347, PMID 18545693, PMID 18612426, PMID 18698359, PMID 18930565, PMID 19093004, PMID 19390585, PMID 19569965, PMID 19607731, PMID 19641203, PMID 19673614, PMID 19855847, PMID 20107498
2019 (3), 2015 (2), 2016 (2), U01CI000211 (2), 2014 (1), 2017 (1), 2018 (1), 5UM1AI148684-04 (1), N01AI085346 (1), R01AI025136 (1), R01HL086488 (1), R01HL130763 (1), R01NS074409 (1), U01AI065683 (1), U19AI065683 (1)